Core Viewpoint - Katapult Holdings held its Third Quarter 2025 Earnings Call, discussing financial performance and future guidance [2]. Group 1: Financial Performance - The call included remarks from key executives, including the CEO, CFO, and Chief Growth Officer, indicating a focus on operational results and financial guidance [2]. - The company provided both GAAP and non-GAAP financial measures, emphasizing the importance of understanding these metrics in evaluating performance [3]. Group 2: Forward-Looking Statements - The executives made forward-looking statements regarding financial guidance and business operations, highlighting the inherent risks and uncertainties associated with these projections [3]. - The company noted that actual results may differ materially from these forward-looking statements, which are based on current beliefs and assumptions [3].

Core Insights - Assertio Holdings reported strong financial results for Q3 2025, with significant growth in net product sales, particularly for Rolvedon, which saw sales increase to $38.6 million from $15.0 million year-over-year [7][2] - The company has narrowed its FY2025 net product sales guidance to a range of $110 million to $112 million and adjusted EBITDA guidance to $14 million to $16 million [5][1] - Paul Schwichtenberg has been promoted to President and COO, indicating a strategic focus on operational efficiency and commercial execution [6][8] Financial Performance - Rolvedon net product sales reached $38.6 million in Q3 2025, a 157% increase from $15.0 million in Q3 2024 [7] - Sympazan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior-year quarter [7] - Indocin net product sales decreased to $4.8 million in Q3 2025 from $5.7 million in Q3 2024 due to generic competition [7] - Gross margin was reported at 72%, down from 74% in the prior-year quarter, attributed to a higher proportion of Rolvedon sales [7] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in Q3 2024 [7] Guidance and Outlook - The updated guidance for FY2025 reflects the impact of the Rolvedon pull-forward and improved visibility into expected performance for the remainder of the year [5][2] - The company expects uninterrupted patient supply of Rolvedon, with regular sales of the newly labeled product anticipated to begin in Q2 2026 [7] Leadership Changes - Paul Schwichtenberg's promotion to President and COO is aimed at enhancing commercial strategies and driving future growth [8][6] - Schwichtenberg has a history of leadership roles within the company, focusing on operational and commercial execution [8]

Core Insights - Aeries Technology held its Second Quarter Fiscal 2026 Earnings Conference Call to discuss results for the quarter ended September 30, 2025, and outline strategic priorities for future growth [1]. Financial Performance - The call included discussions on Aeries' expectations regarding future performance and market opportunities, indicating a focus on growth and strategic direction [2]. Strategic Priorities - The leadership team, including CEO Ajay Khare and CFO Daniel Webb, is set to review the company's strategic priorities that will shape the next stage of growth [1].

Financial Performance - Revenue for Q3 2025 was $1602 million, a 1% increase compared to Q3 2024[13] - Adjusted EBITDA for Q3 2025 was $518 million, with a 323% Adjusted EBITDA margin[13] - Adjusted diluted EPS for Q3 2025 was $101, compared to $087 in Q3 2024, a 16% increase[13] - The full-year revenue range is revised to $6200 million - $6250 million, with an Adjusted EBITDA margin guidance revised to approximately 310%[13] - Free Cash Flow before one-time costs YTD September 2025 was $813 million, compared to $693 million in 2024[32] Revenue Analysis by Segment - Total Women's Health revenue was $429 million in Q3 2025, a decrease of 3% compared to Q3 2024[17] However, year-to-date Women's Health revenue increased by 3% to $1354 million[15,17] - Nexplanon revenue was $223 million in Q3 2025, a decrease of 8% compared to Q3 2024[17] - Total Biosimilars revenue was $196 million in Q3 2025, a 19% increase compared to Q3 2024[20] Year-to-date Biosimilars revenue increased by 2% to $510 million[20] - Hadlima revenue increased by 57% to $63 million in Q3 2025[20] - Total Established Brands revenue was $956 million in Q3 2025, a 1% increase compared to Q3 2024[24] Year-to-date Established Brands revenue decreased by 5% to $2778 million[24] Geographic Performance - United States revenue increased by 2% to $406 million in Q3 2025[56] - Europe and Canada revenue decreased by 4% to $417 million in Q3 2025[56] - Latin America, Middle East, Russia and Africa revenue increased by 18% to $286 million in Q3 2025[56] Guidance - Full-year revenue guidance is revised to $6200 million - $6250 million, representing a nominal revenue growth of (32%) - (24%)[39] - Adjusted EBITDA margin guidance is revised to approximately 310%[39]

Core Insights - Datadog reported Q3 2025 non-GAAP EPS of 55 cents, a 19.6% increase year-over-year, exceeding Zacks Consensus Estimate by 22.22% [1] - The company's net revenues reached $885.7 million, reflecting a 28.4% year-over-year growth and surpassing the consensus estimate by 4.22% [1] Customer Metrics - Datadog ended Q3 with 32,000 customers, up from approximately 29,200 in the same period last year [2] - The number of customers with an annualized run rate (ARR) of $100,000 or more increased to 4,060, compared to about 3,490 in the prior year, contributing to 89% of total ARR [2] Product Usage - 84% of customers utilized two or more products, an increase from 83% year-over-year [3] - 54% of customers used four or more products, up from 49% in the previous year [3] - The trailing 12-month net revenue retention rate was approximately 120%, an increase from the mid-110% range in the prior year [3] Financial Performance - Non-GAAP gross profit for Q3 increased by 28.4% year-over-year to $718.9 million, with an adjusted gross margin of 81.2% [4] - Research & development expenses rose by 38.2% year-over-year to $269.5 million, accounting for 30.4% of revenues, an increase of 220 basis points [4] - Sales and marketing expenses increased by 25.5% year-over-year to $195.5 million, with a slight contraction in percentage of revenues to 22.1% [5] - General & administrative expenses grew by 28.7% year-over-year to $46.5 million, remaining flat as a percentage of revenues [5] - Non-GAAP operating income was reported at $207.4 million, a 19.8% increase year-over-year, although the non-GAAP operating margin declined by 170 basis points to 23.4% [6] Balance Sheet and Cash Flow - As of September 30, 2025, Datadog had cash, cash equivalents, and marketable securities totaling $4.1 billion, up from $3.9 billion as of June 30, 2025 [7] - Operating cash flow for the quarter was $251 million, an increase from $200 million in the previous quarter [7] - Free cash flow was reported at $214 million, compared to $165 million in the prior quarter [7] Guidance - For Q4 2025, Datadog anticipates revenues between $912 million and $916 million, with non-GAAP EPS expected in the range of 54-56 cents [10] - For the full year 2025, revenues are projected between $3.386 billion and $3.390 billion, with non-GAAP EPS expected to be between $2.00 and $2.02 [10]

Financial Performance - Q3 2025 - Sales reached $448 million, compared to $404 million in the same period of 2024[9, 29] - Adjusted EBITDA stood at $92 million, resulting in an Adjusted EBITDA margin of 20.4%[9, 29] - Adjusted earnings per share (EPS) was $0.69[9, 29] - Adjusted Free Cash Flow was $72 million[9] - Net income was $55 million, with diluted earnings per share at $0.66[10, 29] Balance Sheet and Capital Allocation - The company has $618 million in liquidity[32] - Net Debt to Adjusted EBITDA ratio is 1.0x[32] - $30 million of share repurchases were executed in Q3 2025, with $61 million repurchased year-to-date[32] - The quarterly dividend was increased by 10% to $0.055 per share[32] 2025 Outlook - Sales are projected to be in the range of $1.72 billion to $1.745 billion[33] - Adjusted EBITDA margin is expected to be between 19.50% and 20.0%[33] - Adjusted earnings per share are forecasted to be $2.50 to $2.65[33]

Financial Data and Key Metrics Changes - Total investment income decreased to $1.6 million from $2.2 million year-over-year, reflecting both debt repayments and a slowdown in origination dynamics [13][14] - Net investment income increased to $993,000 compared to $887,000 in the same quarter last year, demonstrating effective expense management [15] - Net asset value (NAV) declined to $53.6 million or $18.06 per share from $19.10 per share sequentially, primarily due to valuation adjustments and dividend payments [16] Business Line Data and Key Metrics Changes - The investment portfolio's fair value was $44.3 million across 19 companies, down from year-end, largely due to significant repayments and valuation adjustments [6][7] - The portfolio mix consisted of 83% debt and 17% equity, with a weighted average yield of 12.2% [7] - 39% of investment income was attributable to non-cash PIK interest, up from 24% in the prior year [14] Market Data and Key Metrics Changes - The market for new deal origination remains sluggish, with borrowers facing tighter credit conditions and higher financing costs [4] - The company noted a greater use of PIK interest by borrowers as they adapt to the current financing environment [4] Company Strategy and Development Direction - The company aims to maintain its dividend through disciplined expense management and strong liquidity, even during periods of muted investment activity [6][17] - The focus is on being selective in deal origination while remaining prepared to capitalize on opportunities as market conditions improve [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging lending environment, highlighting a strong balance sheet with no debt and significant liquidity [18] - There are early signs that anticipated interest rate reductions could stimulate deal origination in the future [19] Other Important Information - The company declared and paid a regular quarterly dividend of $0.29 per share, maintaining this level for three consecutive quarters [5][17] - The company experienced a realized loss of $2.9 million on Tilson Technology Management following its Chapter 11 process [10] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Core Viewpoint - WM Technology, Inc. held its Third Quarter 2025 Earnings Conference Call on November 6, 2025, to discuss financial results and future outlook [1][4]. Financial Performance - The earnings announcement and supporting slide deck are available on the Investor Relations website for stakeholders to review [3]. - The company will discuss both GAAP and non-GAAP financial measures during the call, emphasizing that non-GAAP measures should complement, not replace, GAAP information [4]. Leadership Involvement - The call featured key executives, including CEO Doug Francis and CFO Susan Echard, indicating a strong leadership presence in discussing the company's performance [2]. Forward-Looking Statements - The company will make forward-looking statements regarding business outlook, strategies, and long-term goals, while cautioning that these statements are subject to various risks and uncertainties [3].

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $10.5 million, a 9% increase from $9.6 million in Q3 2024, marking the fifth consecutive quarter of year-over-year growth [5][10] - Gross profit for Q3 2025 was $3.2 million, compared to $0.1 million in Q3 2024, with a gross margin of 30.7%, up from 0.9% in the prior year [12] - Net loss for Q3 2025 was $4.3 million or negative $0.08 per diluted share, an improvement from a net loss of $7.6 million or negative $0.15 per diluted share in Q3 2024 [13] Business Line Data and Key Metrics Changes - Lab Essentials revenue was $8.3 million in Q3 2025, a 16% increase from $7.2 million in Q3 2024, driven by higher average revenue per customer [10][11] - Clinical Solutions revenue was $1.7 million in Q3 2025, a 13% decrease from $2.0 million in Q3 2024, attributed to lower average revenue per customer [11] Market Data and Key Metrics Changes - Approximately 25% of total revenue is derived from custom products purchased by biopharma customers, with the remaining 75% growing in the low double digits [8][16] - The company has seen a steady increase in demand for custom reagents in market segments such as animal health, life science tools, and diagnostics [8] Company Strategy and Development Direction - The company is focused on long-term, sustainable growth, aiming for $200 million in annualized revenue without significant additional capital investments [6] - Investments in distributor management, purchasing integration, and price optimization are expected to drive operational efficiency and revenue growth [6][9] - The company is pursuing potential tuck-in acquisitions and collaborations to enhance capabilities and accelerate growth [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term outlook for end markets, despite current softness in demand for clinical solutions from biopharma customers [19] - The company expects modest growth in custom biopharma products and low double-digit growth in the remaining revenue segments [16][18] Other Important Information - The company reiterated its 2025 total revenue guidance of $39 million to $42 million, expecting to finish slightly below the midpoint of that range [15] - Capital expenditures for Q3 2025 were $0.4 million, with free cash outflow remaining at $2.4 million, consistent with Q3 2024 [15] Q&A Session Summary Question: How have customer conversations trended regarding MFN Pharma Tariffs? - Management noted optimism but indicated that actual purchasing actions have not yet been observed, with limited conversations about ramping up spending [21][22] Question: Update on the RUO Plus initiative? - The initiative is performing well, providing flexibility for customers not ready for GMP, and is seen as a pathway to migrate them to GMP in the future [24] Question: Expected product mix and interest in custom portfolio? - Management highlighted that 75% of the business is growing double digits, with increased interest in tools and diagnostics, indicating a strong performance across all market segments [29][30] Question: Insights on clinical solutions customer acquisition? - Management confirmed ongoing customer acquisition, with a focus on larger-sized customers, and noted that the mix may change but remains positive [36][38] Question: Gross margin improvement trajectory? - Management indicated that gross margin improvements are expected to continue, driven by high fixed costs and ongoing efficiency projects [42][44] Question: Areas for driving more efficiencies? - The company is continuously seeking operational efficiencies across various functions, including labor savings and IT infrastructure improvements [48][50]

Financial Data and Key Metrics Changes - The company reported an adjusted net loss of $3 million in Q3 2025, an improvement from an adjusted net loss of $16 million in Q2 2025, driven by higher lock volume and servicing revenue [12][14] - Pull-through weighted rate lock volume increased by 10% to $7 billion from $6.3 billion in the previous quarter, aligning with guidance [12][16] - Adjusted total revenue rose to $325 million in Q3 2025, compared to $292 million in Q2 2025 [12][14] - The pull-through weighted gain on sale margin was 339 basis points, up from 330 basis points in the prior quarter [13][14] - Total expenses increased by 6% to $19 million, primarily due to one-time benefits recognized in the prior quarter [14][16] Business Line Data and Key Metrics Changes - Loan origination volume decreased by 3% to $6.5 billion in Q3 2025 from $6.7 billion in Q2 2025 [13] - Servicing fee income increased from $108 million in Q2 2025 to $112 million in Q3 2025, reflecting growth in the servicing portfolio [14] Market Data and Key Metrics Changes - The company expects pull-through weighted lock volume in Q4 2025 to be between $6 billion and $8 billion, and origination volume between $6.5 billion and $8.5 billion [16][17] Company Strategy and Development Direction - The company is focused on a diversified business model with best-in-class origination capabilities across multiple channels, aiming to profitably regain market share [5][10] - A business transformation was initiated in Q3 2025, including new leadership across origination channels and technology functions [6][10] - The company is leveraging technology and innovation to improve customer experience and operational efficiency [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to fund growth opportunities and maintain a strong capital structure despite upcoming debt maturities [21][34] - The company anticipates improved profitability with a sustained decrease in mortgage rates, leveraging its direct origination platform and technology investments [18][34] Other Important Information - The company ended Q3 2025 with $459 million in cash, an increase of $51 million from Q2 2025 [17] - The leadership team has been reshaped to focus on profitable market share growth and operational efficiency [10][18] Q&A Session Summary Question: Outlook for funding growth with capital given upcoming debt maturities - Management feels confident about funding growth opportunities and has supportive lender relationships [21] Question: Minimum level of originations needed to return to profitability - Management indicated that profitability is closely tied to margins, which are dynamic and will improve with increased volume [30] Question: Consideration of capital raising when stock price was higher - Management acknowledged the attractiveness of raising capital at higher stock valuations and is exploring various options to strengthen the capital structure [33][34]